Analytical Data
-
Gene name
EP2
- Application
-
Alternative Names
PTGER2; Prostaglandin E2 Receptor(Subtype EP2),53kD
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43116
-
Expression Region
Ala155~Gln355
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EP2 recombinant protein research has gained significant attention due to its potential applications in various fields, including biomedicine and biotechnology. EP2, or prostaglandin E2 receptor subtype 2, plays a crucial role in multiple physiological processes, such as inflammation, immune response, and cellular differentiation. The receptor is linked to various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. Consequently, understanding the function and mechanism of EP2 is vital for developing targeted therapeutic strategies. By utilizing recombinant DNA technology, researchers can produce EP2 proteins in sufficient quantities for detailed study. These proteins facilitate the exploration of their structural characteristics, binding properties, and signaling pathways. Through the development of EP2 antagonists or agonists, scientists aim to modulate its activity for therapeutic benefits. Furthermore, the study of EP2 recombinant proteins can pave the way for novel drug discovery and improved therapeutic interventions. In summary, the investigation of EP2 recombinant proteins is crucial for advancing our understanding of their biological roles and for developing new strategies to combat diseases associated with this receptor.
